Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Revenues up 8% in the Quarter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novartis Revenues up 8% in the Quarter

Growth was mainly driven by Entresto, Kesimpta, Kisqali, Pluvicto and Scemblix.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis
4Q Revenues: $11.4 billion (+8%)
4Q Earnings: $2.6 billion (+101%)
FY Revenues: $45.4 billion (+8%)
FY Earnings: $8.6 billion (+42%)
Comments: Sales growth in the quarter was mainly driven by continued strong performance from Entresto (+27% to $1.6 billion), Kesimpta (+74% to $641 million), Kisqali (+71% cc to $610 million), Pluvicto (+53% to $273 million) and Scemblix (+143% cc to $125 million). Cosentyx sales were $1.3 billion in the quarter, up 21%. Promacta/Revolade sales were %563 million, up 4%. Tafinlar + Mekinist sales were $486 million, up 5%. Tasigna sales were down 6% to $446 million. Jakavi sales were $444 million, up 14%. Lucentis sales were down 24% to $301 million.
 
Earnings growth was driven by higher operating income and non- recurring favorable tax impacts.  During the year, Novartis completed its transformation into a “pure-play” innovative medicines business focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology.
 
Discontinued operations include the Sandoz generic pharmaceuticals and biosimilars division, certain corporate activities attributable to Sandoz prior to the spin-off up to the distribution date of October 3, 2023, and certain other expenses related to the spin-off. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters